UNSPSC 51342404: Saquinavir mesilate or mesylate

This classification denotes a protease inhibitor with the molecular formula C38H50N6O5.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UHB9Z3841A, chemically known as butanediamide, n(sup 1)-(3-(3-(((1,1-dimethylethyl)amino)carbonyl)octahydro-2(1h)-isoquinolinyl)-2-hydroxy-1-(phenylmethyl)propyl)-2-((2-quinolinylcarbonyl)amino)-, (3s-(2(1r*(r*),2s*),3.alpha.,4a.beta.,8a.beta.))-, monomethanesulfonate, but more generally known as saquinavir mesylate, which bears US NIH Compound Identifier 60787.

UNSPSC 51342404 Saquinavir mesilate or mesylate is a Commodity code for a specific antiretroviral pharmaceutical product, but recent state and local procurement activity under this code shows no direct solicitations for saquinavir. The two opportunities tagged to this code involve unrelated pharmaceuticals — one a completed Illinois Department of Public Health piggyback contract for Doxycycline Hyclate and Ciprofloxacin Hydrochloride through the MMCAP Infuse cooperative purchasing vehicle, and the other a Seminole County, Florida procurement for Naloxone and drug deactivation systems. Neither opportunity involves saquinavir, indicating a tagging mismatch or dormant activity under the code's nominal scope.

State and local governments appear to source narrow-spectrum antibiotics and emergency-response pharmaceuticals through cooperative purchasing consortia and county health procurement processes, but the code shows little recent activity aligned with its intended antiretroviral product category. Without concrete evidence of active saquinavir-specific solicitations, pursuit of this code should be deferred pending direct inquiry to state pharmacy benefit managers, Medicaid agencies, or correctional health systems that may source antiretrovirals through non-advertised standing agreements or restricted competitive processes outside typical RFP/RFQ channels.